导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.83% | 1164/4773 |
| 近一周 | -6.31% | 5357/5462 |
| 近一月 | 0.07% | 669/5421 |
| 近一季 | 3.71% | 348/5209 |
| 近半年 | -6.13% | 3019/4920 |
| 近一年 | 10.49% | 993/4366 |
| 近两年 | 103.25% | 583/2954 |
| 近三年 | 54.19% | 500/2253 |
| 成立以来 | 105.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
6.11% 287/4961 |
-11.41% 4282/5312 |
- - |
- - |
| 2025 | 43.70% 654/4813 |
9.16% 417/3635 |
8.18% 345/4076 |
19.01% 2203/4524 |
2.25% 1028/4813 |
| 2024 | -2.66% 2199/3463 |
-15.63% 2549/2808 |
-4.36% 1501/3014 |
11.05% 2560/3129 |
8.62% 381/3463 |
| 2023 | 10.70% 88/2656 |
8.38% 463/2280 |
0.50% 317/2385 |
-2.16% 628/2515 |
3.88% 43/2655 |
| 2022 | -23.27% 1122/2207 |
-13.76% 829/1919 |
6.15% 761/2016 |
-12.17% 660/2113 |
-4.57% 1894/2208 |
| 2021 | -0.21% 744/1822 |
-5.56% 936/1255 |
9.11% 584/1330 |
-4.65% 726/1466 |
1.57% 869/1822 |
| 2020 | 39.26% 340/1250 |
-8.39% 604/1028 |
13.72% 598/1067 |
17.26% 109/1164 |
14.01% 309/1184 |
| 2019 | 32.84% 440/1092 |
23.89% 541/739 |
-1.74% 321/788 |
1.59% 385/850 |
7.43% 433/918 |
| 2018 | -26.44% 385/834 |
- - |
-8.57% 232/631 |
-2.71% 298/660 |
-12.00% 392/682 |
| 2017 | 17.53% 225/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.28% 128/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方大数据300C VS. 长安沪深300非周期A(740101) |